$VPRO SOLID DD ~~~~~ COMPANY & WEBSITE LINKS ~~~~~~
VIROPRO INC.
http://www.viropro.net
SUBSIDIARY
Alpha Biologics
http://www.alphabiologics.com
~~~~~ 6 REASONS TO BUY ~~~~~~
New Top Rate Management >>
http://www.viropro.net/leadership-team/
Auditied Filings and Migration to New Stock Exchange NASDAQ/NYSE
Partnership Agreement worth Hundreds of Millions $$'s with Top Distributor
Share Structure is Amazing at 1.2 Billion with more than 50% Held by Institutions.
Float 39,000,000
Insiders Hold 48,000,000
Spring Hill Bioventures Sdn Bhd
340,000,000
THG Capital Sdn Bhd
184,000,000
Intas Biopharmaceuticals Ltd.
106,916,666
No Dilution No Toxic Debt
~~~~~LATEST NEWS OR FILINGS~~~~~~
Last 2 8-K's Speak Volumes about the Future of VIROPRO, Please read as they are full of Important Facts and really show the New Management Team is getting serious with respect to bringing Value to the Shareholders.
Shareholder Letter >> Current Report Filing (8-k)Edgar (US Regulatory) • Mon Jul 28,2014 8:45 AM
New Management Team >> Current Report Filing (8-k)Edgar (US Regulatory) • Fri Jun 13,2014 7:44 AM
525,000,000 Shares Held >> Amended Statement of Beneficial Ownership (sc 13d/a)Edgar (US Regulatory) • Tue Feb 25,2014 1:12 PM
Current Report Filing (8-k)Edgar (US Regulatory) • Fri Nov 8,2013 10:35 AM
Current Report Filing (8-k)Edgar (US Regulatory) • Thu Nov 7,2013 10:03 AM
~~~~~COMPANY WEBSITE INFO~~~~~~
Company Overview
Viropro is an integrated developer and manufacturer of biopharmaceutical products that address unmet medical need in an efficient and cost-effective way.
Operating primarily through its wholly-owned subsidiary Alpha Biologics, the company has a team of experts and a state-of-the-start production facility that can rapidly move from benchtop to bedside.
We intend to develop our own products for commercial sale as well as make our facility available for contract manufacturing. With access to a highly trained work force and low operating costs, Viropro should be your choice as a development partner for life-saving biotherapeutics.
Alpha Biologics houses a bio-manufacturing facility located in Penang, Malaysia built to US FDA and European EMEA current Good Manufacturing Practices (cGMP) standards. Our 5,000m2 plant located in the Penang Science Park was designed for the manufacture of biologics (including biosimilars) for pre-clinical and Phase I, II and III clinical trials and early stage commercial operations. Within the plant is state-of-the-art custom-made manufacturing equipment, including a 500L bioreactor capacity and room for expansion to commercial scale.
Services
The company’s principal objective is to provide high-yield development and GMP manufacturing services to biopharmaceutical companies in global markets with unmet medical needs.
With its state-of-the-art production facility at the crossroads of rapidly developing markets in Asia, Viropro is uniquely positioned provide rapid and cost-effective scale up for global pharmaceutical development.
Alpha Biologics operates a 55,000 square foot facility located in the Penang Science Park, a short drive from the Penang International Airport. Designed and built by industry experts to the exacting standards necessary for FDA and EMEA cGMP certifciation, the facility is ideally suited for scale-up and early commercial production of biosimilars, biobetters and novel drug delivery technologies.
Uniquely Compelling Advantages
Brand new state-of-the-art facility and equipment expressly designed to shorten production time and minimize costs Lower operational cost and service fees Facility pre-designed for expansion as needed Same equipment in PD and GMP areas – minimizes risk and tech transfer time No IP, platform technology, etc. complications Malaysia is a member of PIC/Opportunity for Halal certification of facility/processes
Investor Overview
Viropro is a publicly traded company currently listed on the OTC Pink under the ticker VPRO.
The company plans to become fully reporting in the near future and migrate to another stock exchange
~~~~~ CHARTS ~~~~~~
VPRO Daily Chart >>http://stockcharts.com/h-sc/ui?s=VPRO&p=D&b=5&g=5&id=p13283364476
VPRO Weekly Chart >> http://stockcharts.com/h-sc/ui?s=VPRO&p=W...1727910178
~~~~~ OTHER INFORMATION ~~~~~~
Portfolio Valuation
Viropro estimates the combined, aggregate realizable value of its biosimilars portfolio to be in the range of $33 million to $42 million, depending upon market dynamics of the individual products.
The products include biosimilar version of Avastin (bevacizumab), Erbitux (cetuximab), Herceptin (trastuzumab), Humira (adalimumab ), Rituxan (rituximab) and a non-disclosed biological used for cancer and immune-disease indications.
The biosimilars are generic versions of Humira, Rituxan, Avastin, Herceptin, Erbitux, and one other non-disclosed biotherapeutic. The companies project that Viropro commercial and manufacturing royalties have the potential to grow to an annual revenue rate of $60–$150 million in 10 years. The partnership plans to launch its first product by late 2014.
Huge Documents Involving Gilead, Celgene, Amgen, Biogene Idec and So Many Top Pharmaceuticals...VIROPRO is a Steal considering the Competitor's Value.... 73 Page Pharmaceutical & Biotechnology 2014 Outlook >> https://www.google.ca/url?sa=t&source=web...7CmJfnK8QA
Active SOS >> https://nvsos.gov/sosentitysearch/CorpDetails...amp;nt7=0j
Employees
The Company has 34 employees. Two of the employees are Viropro’s senior executive officers and seven are employees of BPD. Under Alpha Biologics, there are 20 employees in Penang, Malaysia and 5 in Cambridge, UK.
Competitors Capitalization
Lonza Group AG (SWX:LONN)
$8 billion
Pharmaceutical Product Development, Inc. (Nasadaq
PDI)
$5 billion
Cambrex Corporation (NYSE:CBM)
$682 Million
Bioanalytical Systems, Inc. (Nasdaq:BASI)
$20 Million
Viropro,Inc. (PINK :VPRO)
$9.5 million
VIROPRO INC. is the Absolute amazing Bio similar play. Which many of your top rate companies patents are expiring in 2017. Giving VPRO a huge head start on the future of Biosimilars which is expected to top $30 Billion by 2020.
5 PATENTS USES and 1 Undisclosed >>
Bevacizumab (pronounced /bev-a-Sizz-uh-mab/,[1] trade name Avastin,Genentech/Roche) is an angiogenesis inhibitor, as a drug that slows the growth of new blood vessels. It is licensed to treat various cancers, including colorectal, lung, breast (outside the USA), glioblastoma (USA only), kidney and ovarian.
b]Cetuximab (Erbitux)[/b] is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer [1] andhead and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is manufactured and distributed in the United States by the drug companies Bristol-Myers Squibb and Eli Lilly and Company and in Europe by the drug company Merck KGaA.
Trastuzumab (INN; trade names Herclon,Herceptin) is a monoclonal antibody that interferes with the HER2/neu receptor. Its main use is to treat certain breast cancers.
Adalimumab , trade name Humira, is a TNF inhibiting anti-inflammatory drug. AbbVie's trade name is derived from the acronym of "human monoclonal antibody in rheumatoid arthritis" (HUMIRA). Adalimumab binds totumor necrosis factor-alpha (TNFα), preventing it from activating TNF receptors; TNFα inactivation has proven to be important in downregulating the inflammatory reactions associated with autoimmune diseases. Adalimumab has been approved in the United States for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis and juvenile idiopathic arthritis.
Rituximab (trade names Rituxan, MabTheraand Zytux) is a chimeric monoclonal antibodyagainst the protein CD20, which is primarily found on the surface of immune system B cells. Rituximab destroys B cells and is therefore used to treat diseases which are characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. This includes many lymphomas,leukemias, transplant rejection, andautoimmune disorders.
VIROPRO INC.
http://www.viropro.net
SUBSIDIARY
Alpha Biologics
http://www.alphabiologics.com
~~~~~ 6 REASONS TO BUY ~~~~~~
New Top Rate Management >>
http://www.viropro.net/leadership-team/
Auditied Filings and Migration to New Stock Exchange NASDAQ/NYSE
Partnership Agreement worth Hundreds of Millions $$'s with Top Distributor
Share Structure is Amazing at 1.2 Billion with more than 50% Held by Institutions.
Float 39,000,000
Insiders Hold 48,000,000
Spring Hill Bioventures Sdn Bhd
340,000,000
THG Capital Sdn Bhd
184,000,000
Intas Biopharmaceuticals Ltd.
106,916,666
No Dilution No Toxic Debt
~~~~~LATEST NEWS OR FILINGS~~~~~~
Last 2 8-K's Speak Volumes about the Future of VIROPRO, Please read as they are full of Important Facts and really show the New Management Team is getting serious with respect to bringing Value to the Shareholders.
Shareholder Letter >> Current Report Filing (8-k)Edgar (US Regulatory) • Mon Jul 28,2014 8:45 AM
New Management Team >> Current Report Filing (8-k)Edgar (US Regulatory) • Fri Jun 13,2014 7:44 AM
525,000,000 Shares Held >> Amended Statement of Beneficial Ownership (sc 13d/a)Edgar (US Regulatory) • Tue Feb 25,2014 1:12 PM
Current Report Filing (8-k)Edgar (US Regulatory) • Fri Nov 8,2013 10:35 AM
Current Report Filing (8-k)Edgar (US Regulatory) • Thu Nov 7,2013 10:03 AM
~~~~~COMPANY WEBSITE INFO~~~~~~
Company Overview
Viropro is an integrated developer and manufacturer of biopharmaceutical products that address unmet medical need in an efficient and cost-effective way.
Operating primarily through its wholly-owned subsidiary Alpha Biologics, the company has a team of experts and a state-of-the-start production facility that can rapidly move from benchtop to bedside.
We intend to develop our own products for commercial sale as well as make our facility available for contract manufacturing. With access to a highly trained work force and low operating costs, Viropro should be your choice as a development partner for life-saving biotherapeutics.
Alpha Biologics houses a bio-manufacturing facility located in Penang, Malaysia built to US FDA and European EMEA current Good Manufacturing Practices (cGMP) standards. Our 5,000m2 plant located in the Penang Science Park was designed for the manufacture of biologics (including biosimilars) for pre-clinical and Phase I, II and III clinical trials and early stage commercial operations. Within the plant is state-of-the-art custom-made manufacturing equipment, including a 500L bioreactor capacity and room for expansion to commercial scale.
Services
The company’s principal objective is to provide high-yield development and GMP manufacturing services to biopharmaceutical companies in global markets with unmet medical needs.
With its state-of-the-art production facility at the crossroads of rapidly developing markets in Asia, Viropro is uniquely positioned provide rapid and cost-effective scale up for global pharmaceutical development.
Alpha Biologics operates a 55,000 square foot facility located in the Penang Science Park, a short drive from the Penang International Airport. Designed and built by industry experts to the exacting standards necessary for FDA and EMEA cGMP certifciation, the facility is ideally suited for scale-up and early commercial production of biosimilars, biobetters and novel drug delivery technologies.
Uniquely Compelling Advantages
Brand new state-of-the-art facility and equipment expressly designed to shorten production time and minimize costs Lower operational cost and service fees Facility pre-designed for expansion as needed Same equipment in PD and GMP areas – minimizes risk and tech transfer time No IP, platform technology, etc. complications Malaysia is a member of PIC/Opportunity for Halal certification of facility/processes
Investor Overview
Viropro is a publicly traded company currently listed on the OTC Pink under the ticker VPRO.
The company plans to become fully reporting in the near future and migrate to another stock exchange
~~~~~ CHARTS ~~~~~~
VPRO Daily Chart >>http://stockcharts.com/h-sc/ui?s=VPRO&p=D&b=5&g=5&id=p13283364476
VPRO Weekly Chart >> http://stockcharts.com/h-sc/ui?s=VPRO&p=W...1727910178
~~~~~ OTHER INFORMATION ~~~~~~
Portfolio Valuation
Viropro estimates the combined, aggregate realizable value of its biosimilars portfolio to be in the range of $33 million to $42 million, depending upon market dynamics of the individual products.
The products include biosimilar version of Avastin (bevacizumab), Erbitux (cetuximab), Herceptin (trastuzumab), Humira (adalimumab ), Rituxan (rituximab) and a non-disclosed biological used for cancer and immune-disease indications.
The biosimilars are generic versions of Humira, Rituxan, Avastin, Herceptin, Erbitux, and one other non-disclosed biotherapeutic. The companies project that Viropro commercial and manufacturing royalties have the potential to grow to an annual revenue rate of $60–$150 million in 10 years. The partnership plans to launch its first product by late 2014.
Huge Documents Involving Gilead, Celgene, Amgen, Biogene Idec and So Many Top Pharmaceuticals...VIROPRO is a Steal considering the Competitor's Value.... 73 Page Pharmaceutical & Biotechnology 2014 Outlook >> https://www.google.ca/url?sa=t&source=web...7CmJfnK8QA
Active SOS >> https://nvsos.gov/sosentitysearch/CorpDetails...amp;nt7=0j
Employees
The Company has 34 employees. Two of the employees are Viropro’s senior executive officers and seven are employees of BPD. Under Alpha Biologics, there are 20 employees in Penang, Malaysia and 5 in Cambridge, UK.
Competitors Capitalization
Lonza Group AG (SWX:LONN)
$8 billion
Pharmaceutical Product Development, Inc. (Nasadaq
PDI) $5 billion
Cambrex Corporation (NYSE:CBM)
$682 Million
Bioanalytical Systems, Inc. (Nasdaq:BASI)
$20 Million
Viropro,Inc. (PINK :VPRO)
$9.5 million
VIROPRO INC. is the Absolute amazing Bio similar play. Which many of your top rate companies patents are expiring in 2017. Giving VPRO a huge head start on the future of Biosimilars which is expected to top $30 Billion by 2020.
5 PATENTS USES and 1 Undisclosed >>
Bevacizumab (pronounced /bev-a-Sizz-uh-mab/,[1] trade name Avastin,Genentech/Roche) is an angiogenesis inhibitor, as a drug that slows the growth of new blood vessels. It is licensed to treat various cancers, including colorectal, lung, breast (outside the USA), glioblastoma (USA only), kidney and ovarian.
b]Cetuximab (Erbitux)[/b] is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer [1] andhead and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is manufactured and distributed in the United States by the drug companies Bristol-Myers Squibb and Eli Lilly and Company and in Europe by the drug company Merck KGaA.
Trastuzumab (INN; trade names Herclon,Herceptin) is a monoclonal antibody that interferes with the HER2/neu receptor. Its main use is to treat certain breast cancers.
Adalimumab , trade name Humira, is a TNF inhibiting anti-inflammatory drug. AbbVie's trade name is derived from the acronym of "human monoclonal antibody in rheumatoid arthritis" (HUMIRA). Adalimumab binds totumor necrosis factor-alpha (TNFα), preventing it from activating TNF receptors; TNFα inactivation has proven to be important in downregulating the inflammatory reactions associated with autoimmune diseases. Adalimumab has been approved in the United States for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis and juvenile idiopathic arthritis.
Rituximab (trade names Rituxan, MabTheraand Zytux) is a chimeric monoclonal antibodyagainst the protein CD20, which is primarily found on the surface of immune system B cells. Rituximab destroys B cells and is therefore used to treat diseases which are characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. This includes many lymphomas,leukemias, transplant rejection, andautoimmune disorders.
